Adding fuel to the fire: The growing case for global access to cystic fibrosis transmembrane conductance regulator modulator therapy

Brenda M Morrow¹, Marco Zampoli^{1

2}

Affiliations

¹ Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
² Division of Paediatric Pulmonology, Red Cross War Memorial Children's Hospital, Cape Town, South Africa.

Editorial

Brenda M Morrow et al. Pediatr Pulmonol. 2024 Oct.

. 2024 Oct;59(10):2369-2371.

doi: 10.1002/ppul.27130. Epub 2024 Jun 13.

Brenda M Morrow¹, Marco Zampoli^{1

2}

¹ Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
² Division of Paediatric Pulmonology, Red Cross War Memorial Children's Hospital, Cape Town, South Africa.

No abstract available

References

1. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220‐231. doi:10.1056/NEJMoa1409547
1. Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65‐124. doi:10.1016/S2213-2600(19)30337-6
1. Balfour‐Lynn IM, King JA. CFTR modulator therapies—effect on life expectancy in people with cystic fibrosis. Paediatr Respir Rev. 2022;42:3‐8. doi:10.1016/j.prrv.2020.05.002
1. Gifford AH, Taylor‐Cousar JL, Davies JC, McNally P. Update on clinical outcomes of highly effective modulator therapy. Clin Chest Med. 2022;43(4):677‐695. doi:10.1016/j.ccm.2022.06.009
1. McCoy KS, Blind J, Johnson T, et al. Clinical change 2 years from start of elexacaftor–tezacaftor–ivacaftor in severe cystic fibrosis. Pediatr Pulmonol. 2023;58(4):1178‐1184. doi:10.1002/ppul.26318